Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653569 | 0.83 | TSHR (0.52) | POLBSLC6A3PKMTSHRMLYCD | |
| SCHEMBL308205 | 0.83 | POLB (0.59) | POLBHPGDTSHRKMT2AALDH1A1 | |
| SCHEMBL3814542 | 0.83 | ALDH1A1 (0.46) | POLBHPGDTSHRKMT2AALDH1A1 | |
| SCHEMBL15761206 | 0.82 | UTS2R (0.43) | POLBSLC6A3RAB9APKMHPGD | |
| SCHEMBL3688705 | 0.82 | CYP11B1 (0.48) | POLBSLC6A3RAB9APKMHPGD | |
| SCHEMBL5696214 | 0.82 | CYP2D6 (0.39) | HPGDKMT2AALDH1A1MEN1CFTR | |
| SCHEMBL307136 | 0.81 | MLYCD (0.42) | POLBSLC6A3RAB9APKMHPGD | |
| SCHEMBL13694021 | 0.81 | TSHR (0.42) | POLBSLC6A3RAB9APKMHPGD | |
| SCHEMBL14916617 | 0.81 | CES2 (0.42) | RAB9AKMT2AALDH1A1GAACES2 | |
| SCHEMBL8577021 | 0.81 | POLB (0.41) | POLBSLC6A3RAB9APKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964509-B1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO LTD (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20220213085-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | POLB 4131/4885SLC6A3 2165/4885RAB9A 241/4885 |
| US-20220213085-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HLA-B, HLA-A, SLC10A1 | POLB 89/4885SLC6A3 3712/4885RAB9A 1288/4885 |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | HLA-B, HLA-A, SLC10A1 | POLB 89/4885SLC6A3 3712/4885RAB9A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.